CardioMPO™ Intended Use
CardioMPO™ is an enzyme immunoassay intended for the quantitative determination of myeloperoxidase in human plasma, to be used in conjunction with clinical history, ECG and cardiac biomarkers to evaluate patients presenting with chest pain that are at risk for major adverse cardiac events, including myocardial infarction, need for revascularization, or death.
Background
MPO is an enzyme that is synthesized and stored within polymorphonuclear leukocytes (PMN’s) and monocytes. MPO generates an array of reactive oxidants and free radical species as part of its role in host defenses. These same reactive species can inflict oxidative damage on biological targets, including lipids and proteins. MPO and many of its oxidation products are enriched within human atherosclerotic plaque. Monocytes employ MPO to catalyze low density lipoprotein oxidation within the vessel wall, rendering it into an atherogenic form recognized by macrophage scavenger receptors. MPO may also contribute to the atherosclerotic process by promoting endothelial dysfunction by virtue of its ability to catalytically consume nitric oxide. MPO levels have been shown to be an independent predictor of endothelial dysfunction, angiographically evident CAD, and incident cardiac risks in subjects.
CardioMPO™ Assay
The CardioMPO™ Assay is a sandwich enzyme-linked immunosorbent assay (ELISA) that uses two highly specific monoclonal antibodies, for the measurement of MPO concentration in human lithium heparin plasma. The CardioMPO™ Assay is comprised of the CardioMPO™ Reagent Kit, the CardioMPO™ Calibrator Kit, and the CardioMPO™ Control Kit.
|
|